Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

February 22, 2022

ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Financial Highlights:

  • Revenue of $204.0 million for the fourth quarter of 2021, an increase of 22.2% compared to revenue of $166.9 million for the fourth quarter of 2020, or an increase of 23.0% in constant currency (a non-GAAP measure)1. US revenue of $144.5 million for the fourth quarter of 2021 was 23.7% above the same period a year ago.
  • Revenue of $747.6 million for the full year 2021 compared to revenue of $560.4 million for the full year 2020, or an increase of 32.6% in constant currency1. US revenue of $527.8 million for the full year 2021 was 31.9% above the same period a year ago.

Fourth Quarter 2021 Financial Results
Total revenue increased to $204.0 million for the fourth quarter of 2021 compared to $166.9 million for the fourth quarter of 2020, an increase of 22.2%, or 23.0% in constant currency1. The United States represented 71% of total revenue and international represented 29% of total revenue for the fourth quarter of 2021. Revenue from sales of vascular products grew to $113.6 million for the fourth quarter of 2021, an increase of 30.4% or 31.1% in constant currency1. US vascular revenue and international vascular revenue increased 26.9% and 56.6%, respectively, compared to the fourth quarter of 2020. Revenue from sales of neuro products grew to $90.4 million for the fourth quarter of 2021, an increase of 13.3% or 14.1% in constant currency1. US neuro revenue increased 17.6% while international neuro revenue increased 9.0% compared to the fourth quarter of 2020.

Gross profit for the fourth quarter of 2021 was $125.4 million, or 61.5% of total revenue and was impacted by higher labor and logistics costs due to the impact of inflation. This compares to gross profit of $94.3 million, or 56.5% of total revenue, for the fourth quarter of 2020, which includes the one-time unfavorable impact of $18.4 million from the December 2020 voluntary recall of the Jet 7 Reperfusion Catheter with Xtra Flex technology ("December 2020 voluntary recall").

Total operating expenses were $165.5 million, or 81.1% of total revenue for the fourth quarter of 2021, including a one-time $25.8 million expense associated with the accelerated vesting of options related to the Sixense acquisition, $15.0 million of non-recurring personnel-related expenses associated with the achievement of R&D milestones for our Thunderbolt product, and a $1.8 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. Excluding these charges, total non-GAAP operating expenses1 were $123.0 million or 60.3% of total revenue for the fourth quarter of 2021. This compares to GAAP and non-GAAP operating expenses of $96.1 million, or 57.6% of total revenue for the fourth quarter of 2020.

Operating loss was $40.1 million for the fourth quarter of 2021. Excluding the charges associated with the one-time accelerated vesting of options related to the Sixense acquisition, non-recurring personnel-related expenses associated with the achievement of R&D milestones for our Thunderbolt product, and amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, non-GAAP operating income1 was $2.5 million for the fourth quarter of 2021. This compares to a GAAP and non-GAAP operating loss of $1.7 million for the fourth quarter of 2020, which includes the one-time unfavorable impact of $18.4 million from the December 2020 voluntary recall.

Full Year 2021 Financial Results
Total revenue increased to $747.6 million for the year ended December 31, 2021 compared to $560.4 million for the year ended December 31, 2020, an increase of 33.4%, or 32.6% in constant currency1. The United States represented 71% of total revenue and international represented 29% of total revenue for the year ended December 31, 2021. Revenue from the sales of vascular products grew to $408.9 million for the year ended December 31, 2021, an increase of 52.7%, or 52.3% in constant currency1. US vascular revenue increased 52.6%, while international vascular revenue increased 53.1% compared to the year ended December 31, 2020. Revenue from the sales of neuro products grew to $338.7 million for the year ended December 31, 2021, an increase of 15.7%, or 14.6% in constant currency1. US neuro revenue increased 3.2%, and international neuro revenue increased 32.7% compared to the year ended December 31, 2020.

Gross profit for the year ended December 31, 2021 was $475.4 million, or 63.6% of total revenue. This compares to gross profit of $338.2 million, or 60.3% of total revenue, for the year ended December 31, 2020, which includes the one-time unfavorable impact of $18.4 million from the December 2020 voluntary recall.

Total operating expenses for the year ended December 31, 2021 were $482.9 million, or 64.6% of total revenue, including a one-time $25.8 million expense associated with the accelerated vesting of options related to the Sixense acquisition, $15.0 million of non-recurring personnel-related expenses associated with the achievement of R&D milestones for our Thunderbolt product, and a $1.8 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. This compares to total operating expenses of $377.1 million, or 67.3% of total revenue, for the year ended December 31, 2020, which includes $20.7 million of one-time, non-recurring personnel-related expenses associated with the launch of our Lightning product. Excluding the charges noted above, total non-GAAP operating expenses1 were $440.3 million, or 58.9% of total revenue during the year ended December 31, 2021, and $356.5 million, or 63.6% of total revenue during the year ended December 31, 2020, respectively.

Operating loss was $7.5 million for the year ended December 31, 2021. Excluding the charges associated with the one-time accelerated vesting of options related to the Sixense acquisition, non-recurring personnel-related expenses associated with the achievement of R&D milestones for our Thunderbolt product, and amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, non-GAAP operating income1 was $35.0 million for the year ended December 31, 2021. Operating loss was $38.9 million for the year ended December 31, 2020. Excluding the charge associated with one-time, non-recurring personnel-related expenses associated with the launch of our Lightning product, non-GAAP operating loss1 was $18.3 million for the year ended December 31, 2020.

Full Year 2022 Financial Outlook
Penumbra projects total revenue for 2022 to be in the range of $860 million to $875 million, which represents growth of 15% to 17% over 2021 revenue of $747.6 million.

Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss financial results for the fourth quarter and year ended December 31, 2021 after market close on Tuesday, February 22, 2022 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 330-2443 for domestic callers and international callers (conference id: 4604622), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for two weeks following the completion of the call.

About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency and b) non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP diluted earnings per share ("EPS").

Constant currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.

Non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:

  • the effects of non-recurring expenses associated with the achievement of R&D milestones for our Thunderbolt product and our Lightning launch;
  • the effects of the one-time expense associated with the accelerated vesting of options and the amortization of acquired intangible assets over their estimated useful lives in connection with the Sixense acquisition; and
  • the excess tax benefits associated with share-based compensation arrangements.

Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.

Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the items referred to above.

The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, which we expect to file with the SEC on or before March 1, 2022. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

 

Penumbra, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands)




December 31,



2021


2020

Assets





Current assets:





     Cash and cash equivalents


$             59,379


$             69,670

     Marketable investments


195,496


195,162

     Accounts receivable, net


133,940


114,608

     Inventories


263,504


219,527

     Prepaid expenses and other current assets


29,155


18,735

          Total current assets


681,474


617,702

Property and equipment, net


58,856


48,169

Operating lease right-of-use assets


131,955


41,192

Finance lease right-of-use assets


36,276


38,065

Intangible assets, net


90,618


10,639

Goodwill


166,388


8,372

Deferred taxes


65,698


50,139

Other non-current assets


12,985


8,705

          Total assets


$        1,244,250


$           822,983

Liabilities and Stockholders' Equity





Current liabilities:





     Accounts payable


$             13,421


$             14,109

     Accrued liabilities


99,796


85,795

     Current operating lease liabilities


8,267


4,697

     Current finance lease liabilities


1,713


1,331

          Total current liabilities


123,197


105,932

Non-current operating lease liabilities


137,045


44,183

Non-current finance lease liabilities


26,523


27,066

Other non-current liabilities


3,558


8,014

          Total liabilities


290,323


185,195

Stockholders' equity:





Preferred stock



Common stock


37


36

Additional paid-in capital


910,614


598,299

Accumulated other comprehensive (loss) income


(2,630)


2,541

Retained earnings


45,906


40,622

Total Penumbra, Inc. stockholders' equity


953,927


641,498

Non-controlling interest



(3,710)

Total stockholders' equity


$           953,927


$           637,788

  Total liabilities and stockholders' equity


$        1,244,250


$           822,983

 

Penumbra, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share amounts)




Three Months Ended December 31,


Year Ended December 31,



2021


2020


2021


2020

Revenue


$           204,011


$           166,898


$           747,590


$           560,412

Cost of revenue


78,564


72,585


272,208


222,237

     Gross profit


125,447


94,313


475,382


338,175

Operating expenses:









     Research and development


52,004


19,455


104,552


90,049

     Sales, general and administrative


113,500


76,603


378,331


287,068

          Total operating expenses


165,504


96,058


482,883


377,117

(Loss) from operations


(40,057)


(1,745)


(7,501)


(38,942)

Interest income, net


21


447


938


1,267

Other (expense) income, net


(918)


787


(3,939)


(343)

(Loss) before income taxes


(40,954)


(511)


(10,502)


(38,018)

(Benefit from) income taxes


(16,321)


(3,143)


(13,125)


(18,761)

Consolidated net (loss) income


$            (24,633)


$                2,632


$                2,623


$            (19,257)

Net loss attributable to non-controlling interest


$                     —


$              (1,016)


$              (2,661)


$              (3,555)

Net (loss) income attributable to Penumbra, Inc.


$            (24,633)


$                3,648


$                5,284


$            (15,702)

Net (loss) income attributable to Penumbra, Inc. per share:









Basic


$                (0.66)


$                  0.10


$                  0.14


$                (0.44)

Diluted


$                (0.66)


$                  0.10


$                  0.14


$                (0.44)

Weighted average shares outstanding:









Basic


37,451,145


36,357,495


36,764,290


35,766,892

Diluted


37,451,145


37,453,842


37,881,180


35,766,892

 

Penumbra, Inc.

Reconciliation of GAAP Operating Expenses and GAAP (Loss) Income From Operations to

Non-GAAP Operating Expenses and Non-GAAP Operating Income (Loss)1

(unaudited)

(in thousands)




Three Months Ended December 31,


Year Ended December 31,



2021


2020


2021


2020










GAAP operating expenses


$             165,504


$               96,058


$             482,883


$             377,117

GAAP total operating expenses includes the effect of the
following items:









Expenses associated with the achievement of Thunderbolt R&D milestones and Lightning launch, respectively


15,000



15,000


20,652

Accelerated vesting of options related to the acquisition of Sixense


25,760



25,760


Amortization of finite lived intangible assets acquired


1,785



1,785


Non-GAAP operating expenses


$             122,959


$               96,058


$             440,338


$             356,465










GAAP (loss) income from operations2


$              (40,057)


$                (1,745)


$                (7,501)


$              (38,942)

GAAP (loss) income from operations includes the effect of the following items:









Expenses associated with the achievement of Thunderbolt R&D milestones and Lightning launch, respectively


15,000




15,000


20,652

Accelerated vesting of options related to the acquisition of Sixense


25,760



25,760


Amortization of finite lived intangible assets acquired


1,785



1,785


Non-GAAP operating income (loss)2


$                 2,488


$                (1,745)


$               35,044


$              (18,290)













1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

GAAP loss from operations and Non-GAAP operating loss for the three and twelve months ended December 31, 2020 include the one-time unfavorable impact of $18.4 million from the December 2020 voluntary recall.

 

Penumbra, Inc.

Reconciliation of GAAP Net (Loss) Income and GAAP Diluted EPS to Non-GAAP Net Income (Loss) and Non-GAAP Diluted EPS1

(unaudited)

(in thousands, except per share amounts)




Three Months Ended
December 31, 2021


Three Months Ended
December 31, 2020


Year Ended

December 31, 2021


Year Ended

December 31, 2020



Net (loss)

income


Diluted
EPS


Net
income


Diluted
EPS4


Net
income


Diluted
EPS


Net

loss4


Diluted
EPS4

GAAP net (loss) income


$    (24,633)


$      (0.66)


$      3,648


$       0.10


$      5,284


$       0.14


$   (15,702)


$      (0.44)

GAAP net (loss) income includes the effect of the
following items:

















Expenses associated with the achievement of Thunderbolt R&D milestones and Lightning launch, respectively


15,000


0.39




15,000


0.40


20,652


0.57

Accelerated vesting of options related to the acquisition of Sixense2


25,760


0.68




25,760


0.67



Amortization of finite lived intangible assets acquired


1,785


0.05




1,785


0.05



Tax effect on the non-GAAP adjustments above2


(9,045)


(0.23)




(9,045)


(0.24)


(4,783)


(0.13)

Excess tax benefits related to stock compensation awards


(4,895)


(0.13)


(2,112)


(0.06)


(12,465)


(0.33)


(12,226)


(0.34)

Non-GAAP net income (loss)


$      3,972


$       0.10


$      1,536


$       0.04


$    26,319


$       0.69


$   (12,059)


$      (0.34)


















GAAP diluted EPS




$      (0.66)




$       0.10




$       0.14




$      (0.44)

Non-GAAP diluted EPS3




$       0.10




$       0.04




$       0.69




$      (0.34)


















Weighted average shares outstanding used to
compute:

















GAAP diluted EPS


37,451,145


37,453,842


37,881,180


35,766,892

Non-GAAP diluted EPS3


38,706,721


37,453,842


37,881,180


35,766,892




1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

2For the three and twelve months ended December 31, 2021, management used a combined federal and state tax rate of 23.29% to compute the tax effect of non-GAAP measures. The $9.0 million tax effect above excludes stock-based compensation related to any early exercises and replacement options exercised by foreign employees in connection with the acquisition of Sixense. For the three and twelve months ended December 31, 2020, management used a combined federal and state tax rate of 23.16% to compute the tax effect of non-GAAP measures.

3For the purposes of calculating Non-GAAP diluted EPS for the three months ended December 31, 2021, non-GAAP diluted weighted average shares outstanding of 38,706,721 was used, as the Company had non-GAAP net income in the period.

4GAAP and Non-GAAP net loss and diluted EPS for the three and twelve months ended December 31, 2020, include the one-time unfavorable impact of $18.4 million from the December 2020 voluntary recall.

 

Penumbra, Inc.

Reconciliation of Revenue Change by Geographic Regions to Constant Currency Revenue Growth1

(unaudited)

(in thousands)




Three Months Ended December 31,


Reported Change


FX Impact


Constant Currency Change



2021


2020


$


%


$


$


%

United States


$                 144,483


$                 116,797


$         27,686


23.7 %


$                —


$         27,686


23.7 %

International


59,528


50,101


9,427


18.8 %


1,262


10,689


21.3 %

Total


$                 204,011


$                 166,898


$         37,113


22.2 %


$           1,262


$         38,375


23.0 %







Year Ended December 31,


Reported Change


FX Impact


Constant Currency Change



2021


2020


$


%


$


$


%

United States


$                 527,789


$                 400,270


$       127,519


31.9 %


$                —


$       127,519


31.9 %

International


219,801


160,142


59,659


37.3 %


(4,395)


55,264


34.5 %

Total


$                 747,590


$                 560,412


$       187,178


33.4 %


$         (4,395)


$       182,783


32.6 %

 

Penumbra, Inc.

Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1

(unaudited)

(in thousands)




Three Months Ended December 31,


Reported Change


FX Impact


Constant Currency Change



2021


2020


$


%


$


$


%

Vascular


$                 113,565


$                   87,098


$         26,467


30.4 %


$             621


$         27,088


31.1 %

Neuro


90,446


79,800


10,646


13.3 %


641


11,287


14.1 %

Total


$                 204,011


$                 166,898


$         37,113


22.2 %


$          1,262


$         38,375


23.0 %





Year Ended December 31,


Reported Change


FX Impact


Constant Currency Change



2021


2020


$


%


$


$


%

Vascular


$                 408,878


$                 267,783


$       141,095


52.7 %


$         (1,162)


$       139,933


52.3 %

Neuro


338,712


292,629


46,083


15.7 %


(3,233)


42,850


14.6 %

Total


$                 747,590


$                 560,412


$       187,178


33.4 %


$         (4,395)


$       182,783


32.6 %




1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

 

Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-fourth-quarter-and-full-year-2021-financial-results-301487749.html

SOURCE Penumbra, Inc.

IR Contact

investors@penumbrainc.com

media@penumbrainc.com

Penumbra, Inc. Headquarters One Penumbra Place
Alameda, CA 94502
USA